Eclipse Bioinnovations, Inc. (Eclipsebio), the leader in sequencing-based analytics for RNA therapeutics, today announced the acquisition of Terrain Bio, a techbio company specializing in AI/ML RNA design and manufacturing analytics. The acquisition accelerates Eclipsebio’s strategy to deliver an integrated, data-first platform to support RNA therapeutic design, manufacturing, and validation..

Eclipse Bioinnovations, Inc.（Eclipsebio），作为RNA治疗领域基于测序分析的领导者，今天宣布收购专注于AI/ML RNA设计与制造分析的技术公司Terrain Bio。此次收购加速了Eclipsebio的战略，即提供一个集成的、以数据为核心的平台，以支持RNA治疗的设计、制造和验证。

Terrain Bio has developed advanced machine learning models for RNA sequence optimization and active learning workflows, alongside a best-in-class R&D-scale mRNA manufacturing platform, to connect computational design directly with experimental feedback. By integrating these capabilities with Eclipsebio’s established sequencing-based datasets and quality control platforms, including eMERGE™ and eVERSE™, Eclipsebio will offer partners a unified Design, Make, Test solution that continuously improves as new data are generated in the development of RNA-based medicines..

Terrain Bio 开发了用于 RNA 序列优化和主动学习工作流程的先进机器学习模型，同时还建立了业界领先的研发规模 mRNA 制造平台，以将计算设计与实验反馈直接连接起来。通过将这些能力与 Eclipsebio 现有的基于测序的数据集和质量控制平台（包括 eMERGE™ 和 eVERSE™）相结合，Eclipsebio 将为合作伙伴提供一个统一的“设计、制造、测试”解决方案，该方案会在 RNA 药物开发过程中随着新数据的生成不断改进。

“This acquisition meaningfully advances our vision for Eclipsebio,” said Peter Chu, CEO of Eclipsebio. “Terrain Bio’s proven AI design capabilities strongly complement our sequencing-first analytics, allowing us to support RNA drug developers earlier in development while continuing to deliver the deep sequencing-based validation our partners rely on for confident decision-making.”.

“这次收购有力地推动了我们对Eclipsebio的愿景，”Eclipsebio首席执行官Peter Chu表示。“Terrain Bio经过验证的AI设计能力与我们以测序为主的分析方法高度互补，使我们能够在RNA药物开发的早期阶段为开发者提供支持，同时继续提供我们合作伙伴所依赖的基于深度测序的验证，助力他们做出明智决策。”

The combined platform will enable RNA therapeutic developers to:

联合平台将使RNA治疗开发者能够：

Iteratively design optimized RNA constructs using AI modeling and active learning;

使用人工智能建模和主动学习迭代设计优化的RNA构建体；

Measure structure, translation, and impurities with high-resolution sequencing analytics; and

使用高分辨率测序分析来测量结构、翻译和杂质；

Gain actionable insight into manufacturing robustness and quality-by-design.

获得对制造稳健性和质量源于设计的可操作洞察。

“Eclipsebio’s deep expertise in sequencing-based validation and curated data repository makes this combination uniquely powerful,” said Chetan Tadvalkar, CEO of Terrain Bio. “Together, we close the gap between computational design and real-world experimental validation, helping RNA therapeutics reach the clinic faster and with greater confidence.”.

“Eclipsebio在基于测序的验证和精心策划的数据存储库方面的深厚专业知识使这种组合具有独特的强大优势，”Terrain Bio首席执行官Chetan Tadvalkar表示。“我们共同弥合了计算设计与现实世界实验验证之间的差距，帮助RNA疗法更快、更可靠地进入临床。”

Eclipsebio will continue to support existing Terrain Bio customers and will work closely with their partners to ensure a seamless transition.

Eclipsebio 将继续支持现有的 Terrain Bio 客户，并将与他们的合作伙伴密切合作，确保无缝过渡。

About Eclipsebio

关于Eclipsebio

Eclipsebio is a private biotechnology company headquartered in San Diego developing first-in-class technologies, analytics, and platforms for the development of tomorrow’s RNA-based and RNA-targeting therapies. With the company’s extensive experience in supporting early-stage basic research through to evaluating preclinical therapies, Eclipsebio provides unparalleled support for obtaining deep insights into RNA and therapeutic biology.

Eclipsebio是一家总部位于圣地亚哥的私营生物技术公司，致力于开发首创的技术、分析工具和平台，以推动未来基于RNA和靶向RNA的治疗方法的发展。凭借公司在支持早期基础研究到评估临床前疗法方面的丰富经验，Eclipsebio为深入洞察RNA和治疗生物学提供了无与伦比的支持。

The company offers its solutions as end-to-end partnerships for biopharma and project-based services for academics. For more information about Eclipsebio, visit www.eclipsebio.com..

该公司为其生物制药领域的解决方案提供端到端的合作伙伴关系，并为学术界提供基于项目的服务。有关Eclipsebio的更多信息，请访问www.eclipsebio.com。

About Terrain Bio

关于Terrain Bio

As an AI-first mRNA CRO, Terrain Bio has developed a technology stack that explores a vast design space of RNA sequences to identify optimized candidates for expression, durability, and function. This tech stack is paired with a wet-lab platform capable of rapidly manufacturing and testing RNA constructs at quality levels that meet or exceed industry benchmarks.

作为一家以人工智能为先导的mRNA合同研究组织，Terrain Bio开发了一套技术堆栈，可探索庞大的RNA序列设计空间，以确定在表达、持久性和功能方面优化的候选者。该技术堆栈与一个湿实验室平台相结合，能够快速制造和测试RNA构建体，其质量水平达到或超过行业基准。

Together, these capabilities allow partners to efficiently design, build, and evaluate RNA sequences, accelerating progression toward viable drug candidates and enabling faster IND submissions..

这些能力共同使合作伙伴能够高效设计、构建和评估 RNA 序列，加快进展到可行的候选药物，并实现更快的 IND 申报。

Contacts

联系人

For media: press@eclipsebio.com

媒体联系：press@eclipsebio.com

For partnerships and platform inquiries: info@eclipsebio.com

合作伙伴关系和平台咨询：info@eclipsebio.com

Source: businesswire.com

来源：businesswire.com